the international society for bipolar disorders (isbd) task force report on antidepressant use in...
TRANSCRIPT
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
November 2014
David L. Fogelson, M.D.
Clinical Professor of Psychiatry
David Geffen School of Medicine at UCLA
And The Semel Institute for Neuroscience and Human Behavior at UCLA
Seeking Consensus recommendations on Antidepressants in Bipolar Disorder
Systematic Review of the Literature Serial Consensus Revisions created final
recommendations Weak evidence base for efficacy and safety of
antidepressants Insufficient evidence to support benefits when
combined with mood stabilizers Major concern that they cause switching May be used on a case by case basis Never prescribe without mood stabilizers in Bipolar I
patients
Sparse High-Quality Clinical DataDifficult to formulate sound clinical
recommendationsDevelop Consensus formed by clinical and
academic expertsAssembled a global panel of expertsDeveloped a process for Literature Review
Literature Review & ConsensusPeer-reviewed ResearchReviewsMeta-analysesClinical trial ReportsFrom these sources developed initial summaryThese findings were then subject to expert
consensusAnd integrated with clinical experience and judgmentTo create final guidelines
Literature Search PubMedTCAsTetracyclicsMAOIsBupropionSSRIs & SNRIsMirtazapine & MianserinTrazodone & NefazodoneAgomelatine
Review Methods Rated Reports methodologically as poor (1-2) or good (3-5) Rated Overall Quality of Evidence A, B, C, or D Statements of use in Bipolar Disorder were created
Acute treatment Maintenance treatment Monotherapy Switch to Mania, hypomania, or mixed states & rapid
cycling Use in mixed states Drug Class
Statements rated as essential or important by 80% of experts made the cut
Rerated Items Items rated as essential or important by 65%-
79% of panel were rerated Items rerated once, either they made 80% cut or
were dropped Items not included by 65% on first cut were
dropped12/25 items were endorsed and form the final
recommendations
Antidepressant Monotherapy widely regarded as contraindicated for bipolar disorder
because weak evidence for efficacy, potential risk for excessive mood elevation (switches)
Imipramine monotherapy > switches than lithium plus IMI IMI monotherapy = lithium for prophylaxis; IMI was not better
than Lithium; Lithium is an effective antidepressant Largest study QTP v Paroxetine v Placebo
740 acutely depressed patients QTP (600 or 300) > paroxetine = PB
Bipolar II Depression: Escitalopram, FLX, some efficacy without switching
Conclusions: Antidepressant MonotherapyInadequate support for efficacy in acute Bipolar Depression
Evidence base is poor, rated D, inconclusive
Evidence base is C in Bipolar II, but marred by methodological shortcomings and selective reporting
Adjunctive antidepressants:short-term efficacy in acute depression Mixed results in two large trials
N = 377; OLZ v OLZ +FLX v PB; OLZ+FLX>OLZ/PB; limitations, no FLX arm and drop out rate of 38.5%
N = 366; Lithium v VPA v CBZ; random assignment to adjunctive bupropion, paroxetine, or PB. BuP = PX = PB; limitations patients already well treated & required sustained improvement
Smaller Studies PX= IMI = PB as adjuncts to mood stabilizers PX v VLFx v PB; as adjuncts to mood stabilizers; single blind;
PX & VLFx > PB
Meta-analyses of Adjunctive antidepressants:short-term efficacy in acute depression Three meta-analyses performed
One was heavily weighted by the FLX-OLZ study One found no difference from placebo A third one found superiority of antidepressants over PB
Naturalistic Study, n = 1,036, found antidepressants to be similarly effective in BPI, BPII, and unipolar depression Predictors of response Prior response Less severe illness course
Conclusions: Adjunctive antidepressants forshort-term efficacy in acute depressionEvidence is B quality for efficacy of FLX-OLZ in
bipolar depressionLack of benefit from Paroxetine or Bupropion Inconsistent for other antidepressantsOverall quality of predictors of response is rated D,
poor.
Adjunctive Antidepressants: Long-term maintenance studies Two randomized controlled trials (no Placebo) BPI
Examined long-term maintenance after favorable short term response VLFx v Bup v Sertraline plus mood stabilizer, one year duration 20 % remained in remission
In those with initial response; more likely to remain in remission when maintained on same medication
Second Study: similar design, antidepressants delayed onset of a depressive episode except in rapid cyclers where they made things worse; no decrease in overall depressive symptoms
Nonrandomized study; antidepressants provided protection by increasing time to relapse and decreasing frequency of relapse into depression
Meta-analysis: Adjunctive Antidepressants, Long-term maintenance studies
Compared with mood stabilizer aloneLittle protection from Depression Increased risk for hypomania and maniaUnfavorable risk-benefit ratio
Conclusions about Adjunctive Antidepressants for Long-Term Maintenance
Few trialsAmbiguous, inconclusive findingsLack of adequate controls & enriched patient
samples led to a D rating of evidence
Antidepressant use in Mania and Mixed States No evidence for efficacy Clinically mixed states are associated with the prescription of
antidepressants Most likely related to failure to diagnose Bipolar Disorder Incorrect diagnoses include: Panic Disorder & Agitated
Depression Overall the quality of the evidence to support this approach is
rated a D
Safety: Antidepressants and Mood SwitchingAntidepressant Associated switches into
hypomania, mania, or mixed states is controversialDifficult to attribute causalitySwitching occurs over the natural course of the
illnessFew Randomized trials of mood stabilizer v mood
stabilizer plus antidepressantQuality of studies is poor
Safety: Differential Association of Types of Antidepressants with Mood Switches 8 week prospective trial, bupropion v. desipramine
5/10 DMI patients switched 1/10 BP patients switched
Several Pb controlled trials with mood stabilizers No elevated switch rate associated with SSRIs or BP For example, 10.1% with SSRI or BP plus mood stabilizer v. 10.7% on
mood stabilizer alone Even in Monotherapy with antidepressants
Paroxetine did not cause more switching than Pb In a 12 month study Sertraline and BP associated with a 10% switch
rate v. 29% for venlafaxine In a 6 week study VLFX > Paroxetine
Is mood switching associated with antidepressants limited to certain classes of antidepressants? Are tricyclics, tetracyclics, & SNRIs riskier? Meta-analyses have reviewed this question This work group concludes the answer is yes. They deem SSRIs and MAOIs as less risky Bupropion may also be less risky It is unknown if Mood stabilizers protect from antidepressant
associated switching
Is there less risk for antidepressant associated switches in Bipolar 2 patients?
Four studies suggest a low risk with antidepressant monotherapy
Meta-analytic review of 13 studies supports Bipolar I patients have higher anti-depressant associated switch rate; relative risk 1.78
The meta-analysis suggested that switches into hypomania may be problematic for Bipolar 2 patients
Clinical Correlates of risk for antidepressant associated switching Retrospective Studies of Mood Stabilizers and adjunct
antidepressants Subsyndromal manic symptoms associated with
Increased risk of switch to hypomania/mania More severe manic episodes Higher rates of unsatisfactory response to antidepressants
History of Suicide attempt/aggressive-disruptive behaviors Higher risk of switching
Patients presenting with Major Depression Higher risk of switching if “bipolar features” present Higher risk if history of antidepressant treatment resistance
Conclusions: Mood Switching Associated with Antidepressants Risk is greater in Bipolar 1 patients compared to Bipolar 2 Risk is greater with tricyclics, tetracyclics, and SNRIs Quality of evidence is rated C
Are newly emerging/increasing irritability and agitation during antidepressant Rx a form of switching? Irritable dysphoria associated with antidepressant treatment
may be more likely in patients with a history antidepressant associated switching
Agitated depression with new onset insomnia, impulsivity, suicidal preoccupation associated with antidepressant Rx
Agitated depression and irritable dysphoria decrease with discontinuation of antidepressant and treatment with mood stabilizers
The evidence is poor to answer this question and is rated D
Antidepressants and Cycle Acceleration Can antidepressants accelerate episode frequency or induce rapid cycling? Case Reports suggest induction of rapid cycling that is persistent Prospective study found those treated with antidepressants were depressed
29% of time v 14.8% for those treated without antidepressants Another prospective trial demonstrated that patients with history of rapid
cycling had three times as many depressive recurrences with continued antidepressant treatment
A non-randomized trial demonstrated that duration of exposure to antidepressants correlated with days ill, mixed episodes, more cycling
One prospective placebo controlled trial of Flx monotherapy found no cycle acceleration or increased risk for relapse Criticisms of this study: selection bias for mild bipolar patients; poor measures
Antidepressants and Cycle Acceleration: Conclusions Quality of evidence is rated D, poor Limitations
Exclusion of rapid cycling patients from clinical studies Lack of baseline cycling rates Lack of placebo comparison Lack of true randomization in studies
Antidepresants and Suicidal Behavior Studies are limited Two retrospective studies find an association of suicidal behaviors with
antidepressants One prospective study of 425 patients found no association of
antidepressants with suicidal behaviors Another prospective study with 184 patients found no association In another prospective study the rate of suicidal behaviors was 35%-
54% lower, risk was lowest in bipolar I disorder Two large studies, over 1,300 patients each, subsyndromal mania is
associated with suicidal behaviors Three studies find that mixed episodes are associated with
antidepressants; mixed episodes are associated with suicidal behaviors
Antidepressants and Suicidal Behavior: ConclusionsEvidence is poor, rated DDifficult to assess due to low rate of suicidal
behaviorsDifficult to design ethical studiesUnable to reach a conclusion as to whether or not
an association exists
International Society for Bipolar Disorders (ISBD) Recommendations for Antidepressant Use in BPD’s
Acute Treatment Adjunctive Antidepressants may be useful for acute Bipolar I or II
depressive episode when there is a history of previous response Adjunctive Antidepressants should be avoided for depression with
two or more co-occurring manic symptoms or psychomotor agitation or rapid cycling
Maintenance Treatment Consider maintenance treatment if depressive relapse occurs off
antidepressant
ISBD Recommendations for Antidepressant Use in BPD’s Monotherapy
Antidepressant Monotherapy should be avoided in BPI depression Antidepressant Monotherapy should be avoided in BPI & II
depression with two or more co-occurring manic symptoms Switch to mania, hypomania, mixed states, or rapid cycling
Bipolar patients starting antidepressants must be closely monitored for mania and agitation
Discontinue antidepressants if signs of mania occur Discourage antidepressant if there is a history of antidepressant
induced mania/agitation Avoid antidepressants in patients with history of rapid cycling
International Society fro Bipolar Disorders (ISBD) Recommendations for Antidepressant Use in BPD’s Use in Mixed States
Avoid antidepressant prescription in patients with predominantly mixed states
Avoid antidepressants in mania/depression with mixed features Discontinue antidepressants if patient is currently in a mixed state
Drug Class Adjunctive treatment with SNRIs or tri- or tetracyclic
antidepressants are second line after other treatments have failed
SNRIs and tri-or tetracyclic antidepressants must be closely monitored because of increased risk for switching or destabilization
Consensus Statements Evidence is limited Evidence is methodologically weak
1. Non-antidepressants should be considered as monotherapy before Rx antidepressants Lithium Lamotrigine Olanzapine Quetiapine Lurasidone
Consensus Statements 2. If antidepressants are prescribed in Bipolar I Disorder they
should be prescribed with a mood stabilizer This recommendation is made even though evidence is
mixed for antidepressant induced mood switching And even though the ability of mood stabilizers to prevent
switching is unproven 3. Antidepressants in acute depression in Bipolar II Disorder
are relatively well tolerated but may or may not be effective 4. Long term prophylactic value is poorly studied in BP I &II
Consensus Statements 5. There is little evidence to support one antidepressant
being more or less effective or more or less dangerous Exceptions are tri- and tetracyclics and venlafaxine, which carry
high risk for inducing elevated mood states 6. Antidepressants can neither be condemned nor endorsed
without consideration of each unique clinical case & presentation